Canaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $587

Benzinga Newsdesk www.benzinga.com Positive 83.4%

Neg 0% Neu 0% Pos 83.4%

Canaccord Genuity analyst Edward Nash maintains Madrigal Pharmaceuticals (NASDAQ:MDGL) with a Buy and raises the price target from $578 to $587.